Icahn Wants to Speak with Enzon Pharma (ENZN) Execs Over Operations, Co. Direction
Tweet Send to a Friend
Activist investor Carl C. Icahn filed an amended 13D with respect to his stake in Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN).
The amended 13D states:
"The Reporting Persons have informed the Issuer that they wish to discuss the operations and direction of the Issuer and the Issuer’s plans to manage expenses and preserve value for shareholders. Following those discussions, the Reporting Persons expect to form a view on the appropriate course of action in respect of the Issuer."
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The amended 13D states:
"The Reporting Persons have informed the Issuer that they wish to discuss the operations and direction of the Issuer and the Issuer’s plans to manage expenses and preserve value for shareholders. Following those discussions, the Reporting Persons expect to form a view on the appropriate course of action in respect of the Issuer."
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Kyle Bass 13G Shows 9.7% Stake in Dex Media (DXM)
- Carl Icahn's Q1 13F Reveals Little New
- Loeb's Third Point LLC Enters Anadarko (APC), NXP Semi (NXPI), Tiffany & Co. (TIF); Exits Herbalife (HLF), Morgan Stanley (MS)
Create E-mail Alert Related Categories
13Ds, Hedge FundsRelated Entities
Carl Icahn, 13D
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
